Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia - Results From Real-life Clinical Studies

Completed

• Conditions: Hyperuricemia

• Registration Number: NCT06652035
• Lead Sponsor: Liaquat University of Medical & Health Sciences

Brief Summary

Quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. Emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. Additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. As a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.

Detailed Description

In the present retrospective cross-sectional observational study, the investigators assessed the potential pharmacological effect of supplemental quercetin on the plasma uric acid levels of health adults. These participants visited nutritional clinics in Italy during the Coronavirus disease (COVID-19) pandemic for general health check-up in real-life to enhance their immune system with supplements aimed at providing additional protection against COVID-19 infection. The supplements, either quercetin or probiotic Streptococcus salivarius K12 (BLIS K12), were advised randomly to the participants for 90 days, tailored to individual needs and in the absence of any pre-defined criteria.

Study Timeline

• Study Start: 2021-09-01
• Primary Completion: 2022-12-31
• Study Completion: 2023-06-15
• Status Verified: 2024-10
• Study First Submitted: 2024-10-16
• Study First Submitted QC: 2024-10-20
• Study First Posted: 2024-10-22
• Last Update Submitted: 2024-10-27
• Last Update Posted: 2024-10-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 161

Inclusion Criteria

• Healthy adults
• BMI between 18.5 and 29.9 kg/m²
• Non-smoker
• Consumtion of less than 3 units of alcohol per day

Exclusion Criteria

• • Plasma uric acid concentrations above 7 mg/dL
• Diagnosis of endocrinological, metabolic, oncological, neurological, or bowel inflammatory disease diseases, gout, kidney stones

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in plasma uric acid level	90 days	Supplement effect on plasma uric acid level

Secondary Outcome Measures

Name	Time	Method
Change in alanine transaminase level	90 days	Supplement effect on liver function
Change in aspartate aminotransferase level	90 days	Supplement effect on liver function
Change in alkaline phosphatase level	90 days	Supplement effect on liver function
Change in gamma-glutamyl transferase level	90 days	Supplement effect on liver function
Change in bilirubin level	90 days	Supplement effect on liver function
Incidence of side effects	90 days	Number of patients reporting side effects
Change in plasma insulin level	90 days	Supplement effect on plasma insulin level
Change in plasma creatine phosphokinase level	90 days	Supplement effect on plasma creatine phosphokinase level
Change in plasma cholesterol level	90 days	Supplement effect on plasma cholesterol level
Change in plasma triglycerides level	90 days	Supplement effect on plasma triglycerides level
Change in plasma glucose level	90 days	Supplement effect on plasma glucose level

Trial Locations

Locations (1)

Dr. Buccomino Medical Clinic; 🇮🇹 Milano, Italy